Ludwig Hantson — Chief Executive Officer. Rare Belonging seeks to advance emotional well-being and educational opportunities and provide relief for critical needs for those living with or affected by a rare disease. The 2020 GAAP and non-GAAP tax rates do not benefit from one-time events that benefited the tax rates in 2019.Long-term debt, less current portionShares used in computing diluted earnings (loss) per common share (GAAP)Income (loss) before income taxesEarnings (loss) per common shareAlexion’s financial guidance is based on current foreign exchange rates net of hedging activities and does not include the effect of acquisitions, license and other strategic agreements, intangible asset impairments, litigation charges, changes in fair value of contingent consideration, gains or losses related to strategic equity investments or restructuring and related activity outside of the previously announced activities that may occur after the issuance of this press release. ALEXION PHARMACEUTICALS, INC. TABLE 2: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (in millions, except per share amounts) (unaudited) Three months ended Twelve months ended December 31, December 31, 2019 2018 2019 2018. Corporate Participants: Morgan Sanford — Director of Investor Relations. Research and development expense:Noncurrent operating lease liabilities(1) The following table summarizes the total restructuring and related expenses recorded by type of activity and the classification within the Reconciliation of GAAP to non-GAAP Financial Results:Current portion of long-term debtIncome tax expense (% of income before income taxes)Acquired in-process research and developmentShares used in computing diluted earnings per common share (non-GAAP)Shares used in computing earnings (loss) per common share(1) Represents contingent milestone payments associated with acquisitions of legal entities accounted for as asset acquisitions.Non-GAAP earnings per common share - dilutedAccounts payable and accrued expensesTotal liabilities and stockholders' equityCurrent portion of contingent considerationNon-GAAP research and development expenseGAAP research and development expenseTax effect of pre-tax adjustments to GAAP net incomeAmortization of purchased intangible assetsGains and losses related to strategic equity investmentsGAAP earnings (loss) per common share - dilutedDiluted GAAP earnings per common shareSelling, general and administrative expense:Operating expense and margin (% total revenues)Diluted non-GAAP earnings per common shareChange in fair value of contingent considerationNon-GAAP selling, general and administrative expenseGAAP selling, general and administrative expenseAmounts may not foot due to rounding.Adjustments to income tax expenseSelling, general and administrative2020 financial guidance assumes a GAAP effective tax rate of 15.5 to 16.5 percent and a non-GAAP effective tax rate of 16.0 to 17.0 percent for the year.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected.Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Finally, we delivered very strong financial performance with 15% revenue growth and … GAAP net income (loss) $ 889.0 $ (45.0) $ 2,404.3 $ 77.6 Before tax adjustments: Please check your download folder.Any amount that you can contribute will help ensure we can keep the site completely free for many years to come.Our goal has always been to serve as an easily accessible, high quality source of investment research for both professionals and amateurs alike.If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page.
Alexion Pharmaceuticals revenue for the twelve months ending March 31, 2020 was $5.296B, a 22% increase year-over-year. Alexion Pharmaceuticals ALXN. Overview: Strong y/y revenue growth. Alexion Pharmaceuticals, Inc. ALXN posted third-quarter 2019 adjusted earnings of $2.79 per share, which surged 38% from the year-ago quarter’s $2.02.Earnings also beat the …